{"prompt": "['A laboratory abnormality may meet the criteria to qualify as an AE as described in this', 'protocol (see Section 7.2). In these instances, the AE corresponding to the laboratory', 'abnormality will be recorded.', 'Laboratory tests for hematology, chemistry, urinalysis, and others are specified in Table 7.', '44']['Table 7. Trial-Related Laboratory Tests', 'Hematology', 'Chemistry', 'Urinalysis', 'Other', 'Hematocrit', 'Albumin', 'Appearance', '-human chorionic gonadotropint', 'Hemoglobin', 'Alkaline phosphatase', 'Color', 'PT (INR)', 'Platelet count', 'Alanine aminotransferase (ALT)', 'pH', 'aPTT', 'WBC (total and differential)', 'Aspartate aminotransferase (AST)', 'Specific gravity', 'Total triiodothyronine (T3)', 'Red Blood Cell Count', 'Lactate dehydrogenase (LDH)', 'Ketones', 'Free thyroxine (T4)', 'Absolute Neutrophil Count', 'Bicarbonate', 'Protein', 'Thyroid stimulating hormone (TSH)', 'Absolute Lymphocyte Count', 'Uric Acid', 'UPCR', 'CRP', 'Absolute Monocyte Count', 'Calcium', 'Glucose', 'Absolute Eosinophil Count', 'Chloride', 'Bilirubin', 'Blood for correlative studies', 'Absolute Basophil Count', 'Glucose', 'Nitrite', 'Phosphorus', 'Creatinine', 'Potassium', 'Urobilinogen', 'Sodium', 'Occult blood', 'Magnesium', '(microscopic examination of sediment will', 'be performed only if the results of the', 'urinalysis dipstick evaluation are positive)', 'Bilirubin', 'Urine pregnancy test t', 'Total protein', 'Blood Urea Nitrogen', 'Amylase', 'Lipase', 'y-glutamyltransferase (GGT)', 't Perform on women of childbearing potential only. Urine or serum testing is allowed. If urine pregnancy results cannot be confirmed as negative, a serum', 'pregnancy test will be required.', '7.1.4 Efficacy Measurements', '7.1.4.1 Tumor Imaging and Assessment of Disease', 'Tumor imaging is strongly preferred to be acquired by computed tomography (CT). For the abdomen and pelvis, contrast-enhanced', 'magnetic resonance imaging (MRI) may be used when CT with iodinated contrast is contraindicated, or when local practice mandates', '45']['it. MRI is the strongly preferred modality for imaging the brain. CT of the brain with IV iodinated contrast is acceptable', 'only', 'if', 'MRI', 'is medically contraindicated. The same imaging technique regarding modality, ideally the same scanner, and the use of contrast should', 'be used in a participant throughout the study to optimize the reproducibility of the assessment of existing and new tumor burden', 'and', 'improve the accuracy of the assessment of response or progression based on imaging.', 'Expedited confirmation of measurable disease based on RECIST 1.1 at Screening should be used to determine participant', 'eligibility.', \"Confirmation that the participant's imaging shows at least 1 lesion that is appropriate for selection as a target lesion per\", 'RECIST', '1.1', 'is', 'required to participant treatment allocation.', '7.1.4.1.1 Initial Tumor Imaging', 'Initial', 'tumor imaging of the brain, chest, abdomen and pelvis at Screening must be performed within 28 days prior to the date of study', 'drug allocation. The site study team must review screening images to confirm the participant has measurable disease per RECIST 1.1.', 'Brain imaging is required to rule out radiographically detectable brain metastases. Magnetic resonance imaging is preferred; however,', 'CT imaging will be acceptable if MRI is medically contraindicated.', '7.1.4.1.2 Tumor Imaging During the Study', 'Imaging', 'assessment during the study can be performed as clinically indicated but there is no scheduled time for assessment within the', '12 weeks between Cycle 1 Day 1 and the completion of 12 weeks of study treatment.', '7.1.4.1.3 End of Treatment and Follow-up Tumor Imaging', 'In participants who complete the 12 weeks of neoadjuvant treatment, tumor imaging should be performed within 14 days of treatment', 'completion such that it is after the last dose of lenvatinib but before surgical resection. If they prematurely discontinue study treatment', 'prior to the 12 weeks, tumor imaging should be performed within 2 weeks of treatment discontinuation if that is > 4 weeks', 'from', 'Cycle', '1 Day 1 of the study. As study enrollment requires localized, non-metastatic disease, abdominal/pelvic imaging is sufficient to assess', 'the extent of the target lesion.', 'Post-nephrectomy and in the long-term follow-up period, every effort should be made to continue monitoring subjects disease status', 'by tumor imaging as per NCCN guidelines for stage III RCC [29]. This includes abdominal imaging within 3 to 6 months of', '46']\n\n###\n\n", "completion": "END"}